Restaurants add protein, fiber for weight loss drug users
CNBC • • general
Key Points:
- The rising adoption of GLP-1 drugs, which reduce appetite and calorie intake, is projected to cut $30 billion to $55 billion annually from the U.S. food and beverage industry's sales by 2030, as these medications lead users to eat less and snack less frequently.
- Approximately one in eight U.S. adults currently take GLP-1 drugs, with usage expected to triple by 2030 due to new oral versions entering the market, expanding the consumer base beyond those willing to use injections.
- The impact is most pronounced in snacking and dining out, particularly at dinner and breakfast, with GLP-1 users reducing restaurant visits by up to 45% in some categories and shifting toward healthier, higher-pro
